Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 05-21 12:15:59 EDT

7.60

+0.40

+5.49%

High7.68	Low7.03	Vol231.07K
Open7.10	D1 Closing7.20	Amplitude9.03%
Mkt Cap237.65M	Tradable Cap119.18M	Total Shares31.29M
T/O1.72M	T/O Rate1.47%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":7.595,"timestamp":1779380130176,"preClose":7.2,"halted":0,"volume":231072,"delay":0,"changeRate":0.05486111111111105,"floatShares":15692500,"shares":31289969,"eps":-3.661292,"marketStatus":"Trading","change":0.395,"latestTime":"05-21 12:15:59 EDT","open":7.1,"high":7.68,"low":7.03,"amount":1715967.591888,"amplitude":0.090278,"askPrice":7.61,"askSize":1,"bidPrice":7.59,"bidSize":17,"shortable":3,"etf":0,"ttmEps":-3.661292,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779393600000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":7.2,"preHourTrading":{"tag":"盘前","latestPrice":7.11,"preClose":7.2,"latestTime":"09:29 EDT","volume":890,"amount":6412.000105,"timestamp":1779370156071,"change":-0.09,"changeRate":-0.0125,"amplitude":0.025},"postHourTrading":{"tag":"盘后","latestPrice":7.2,"preClose":7.2,"latestTime":"16:47 EDT","volume":7378,"amount":53100.51,"timestamp":1779310073144,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.574245,"impliedVol":1.2587,"impliedVolPercentile":0.8924},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2637339080","title":"Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2637339080","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637339080?lang=en_us&edition=fundamental","pubTime":"2026-05-21 21:20","pubTimestamp":1779369640,"startTime":"0","endTime":"0","summary":"The latest update is out from Qyuns Therapeutics Co., Ltd. Class H ( ($HK:2509) ). Qyuns Therapeutics has announced that its partner Zhongmei Huado...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-wins-china-approval-for-ustekinumab-in-crohns-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-wins-china-approval-for-ustekinumab-in-crohns-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637335040","title":"Akari Therapeutics Announces $5.5 Million Private Placement Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335040","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335040?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:30","pubTimestamp":1779366600,"startTime":"0","endTime":"0","summary":"TAMPA, Fla. and LONDON, May  21, 2026  (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299304/0/en/Akari-Therapeutics-Announces-5-5-Million-Private-Placement-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637337003","title":"Tvardi Therapeutics to Participate in Upcoming Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337003","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637337003?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"HOUSTON, May  21, 2026  (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299274/0/en/Tvardi-Therapeutics-to-Participate-in-Upcoming-Investor-Events.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","BK4539","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380640","title":"Hemab Therapeutics Hldgs Q1 EPS $(23.98) Down From $(16.18) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380640","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380640?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:05","pubTimestamp":1779361506,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(23.98) per share. This is a 48.21 percent decrease over losses of $(16.18) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52712224/hemab-therapeutics-hldgs-q1-eps-23-98-down-from-16-18-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638701","title":"Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637638701?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361200,"startTime":"0","endTime":"0","summary":"Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq. Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026  -- Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the first quarter ended March 31, 2026 and noted recent business highlights.\"As a public company we continue our journey to accelerate progress and broaden impact for people living with serious coagulation disorders with strong momentum across our clinical programs,\" said Benny Srensen, Chief Executive Officer of Hemab Therapeutics. \"The Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia recognizes both the potential for sutacimig to address a significant unmet need, and the urgency of ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","BK4539","BK4081","EMA","BK4119","BK4585","GT","COAG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637355382","title":"Buy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2637355382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637355382?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:16","pubTimestamp":1779358582,"startTime":"0","endTime":"0","summary":"Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, retaining the price target of $75.00. Patrick Trucchio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-silence-therapeutics-as-advancing-rnai-pipeline-and-2026-catalysts-support-unchanged-75-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-silence-therapeutics-as-advancing-rnai-pipeline-and-2026-catalysts-support-unchanged-75-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637824688","title":"Trevi Therapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2637824688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637824688?lang=en_us&edition=fundamental","pubTime":"2026-05-21 01:22","pubTimestamp":1779297720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRVI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 13:22 ET (17:22 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636825122","title":"Rani Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2636825122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636825122?lang=en_us&edition=fundamental","pubTime":"2026-05-20 22:45","pubTimestamp":1779288300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RANI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 10:45 ET (14:45 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636836840","title":"DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2636836840","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636836840?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:05","pubTimestamp":1779282310,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics  said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.Shares of DiaMedica rose more than 2% pre-bell Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","DMAC","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636842566","title":"Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2636842566","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636842566?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:26","pubTimestamp":1779280009,"startTime":"0","endTime":"0","summary":"Protara Therapeutics (TARA) has an average rating of Buy and mean price target of $26.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844051","title":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844051","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844051?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:00","pubTimestamp":1779278400,"startTime":"0","endTime":"0","summary":"NEW YORK, May  20, 2026  (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cance","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298417/0/en/Protara-Therapeutics-to-Present-at-the-TD-Cowen-7th-Annual-Oncology-Innovation-Summit-Insights-for-ASCO-EHA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","COWN","BK4127","BK4211","TD","BK4539","BK4566","LENZ","BK4007","BK4207","SMMF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636841106","title":"Protara Therapeutics price target raised to $28 from $25 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2636841106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636841106?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:40","pubTimestamp":1779277248,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on Protara Therapeutics (TARA) to $28 from $25 and keeps an Outperform rating on the shares. TARA-002’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protara-therapeutics-price-target-raised-to-28-from-25-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protara-therapeutics-price-target-raised-to-28-from-25-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636389012","title":"Travere Therapeutics Rides FILSPARI Surge After FDA Win","url":"https://stock-news.laohu8.com/highlight/detail?id=2636389012","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636389012?lang=en_us&edition=fundamental","pubTime":"2026-05-20 12:42","pubTimestamp":1779252164,"startTime":"0","endTime":"0","summary":"Travere Therapeutics, Inc. (($TVTX)) has held its Q1 earnings call. Read on for the main highlights of the call. Travere Therapeutics’ latest earni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/travere-therapeutics-rides-filspari-surge-after-fda-win?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/travere-therapeutics-rides-filspari-surge-after-fda-win?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4539","LENZ","BK4585","BK4139","BK4007","LABU","FFTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636890874","title":"Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2636890874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636890874?lang=en_us&edition=fundamental","pubTime":"2026-05-20 12:33","pubTimestamp":1779251628,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (($ARCT)) has held its Q1 earnings call. Read on for the main highlights of the call. Arcturus Therapeutics’ latest earnings ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arcturus-therapeutics-earnings-call-mrna-bets-vs-burn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arcturus-therapeutics-earnings-call-mrna-bets-vs-burn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867319","title":"Galera Therapeutics Eliminates Series B Preferred, Simplifies Equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867319?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:02","pubTimestamp":1779224544,"startTime":"0","endTime":"0","summary":"An update from Galera Therapeutics ( ($GRTX) ) is now available. On May 15, 2026, Galera Therapeutics, Inc. converted its remaining 42,839.11 share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galera-therapeutics-eliminates-series-b-preferred-simplifies-equity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galera-therapeutics-eliminates-series-b-preferred-simplifies-equity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","EQR","BK4007","BK4139","LENZ","BK4215","BK4539","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636862447","title":"Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2636862447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636862447?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:42","pubTimestamp":1779223331,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics ( ($DCOY) ) has issued an announcement. On May 12, 2026, Decoy Therapeutics Inc.’s board set July 14, 2026, as the date for its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/decoy-therapeutics-sets-2026-annual-shareholder-meeting-date?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/decoy-therapeutics-sets-2026-annual-shareholder-meeting-date?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636864055","title":"Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636864055","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636864055?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:30","pubTimestamp":1779222600,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., May  19, 2026  (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and throm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297984/0/en/Cadrenal-Therapeutics-to-Participate-in-the-Lytham-Partners-Spring-2026-Investor-Conference-on-May-28-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","HIT","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636865638","title":"HLS Therapeutics resumed with a Hold at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2636865638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636865638?lang=en_us&edition=fundamental","pubTime":"2026-05-20 01:25","pubTimestamp":1779211510,"startTime":"0","endTime":"0","summary":"Canaccord resumed coverage of HLS Therapeutics (HLTRF) with a Hold rating and C$5 price target Published first on TheFly – the ultimate source for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hls-therapeutics-resumed-with-a-hold-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hls-therapeutics-resumed-with-a-hold-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","HLTRF","BK4175","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636850402","title":"InMed Pharmaceuticals Announces Reverse Merger with Mentari Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2636850402","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636850402?lang=en_us&edition=fundamental","pubTime":"2026-05-19 23:02","pubTimestamp":1779202940,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) has shared an announcement. On May 19, 2026, InMed Pharmaceuticals and privately held Mentari Therapeutics signed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-announces-reverse-merger-with-mentari-therapeutics-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-announces-reverse-merger-with-mentari-therapeutics-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636852473","title":"Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2636852473","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636852473?lang=en_us&edition=fundamental","pubTime":"2026-05-19 22:15","pubTimestamp":1779200119,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy has maintained their bullish stance on CNTX stock, giving a Buy rating yesterday. Jason McCarthy has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-lifts-price-target-and-reiterates-buy-on-context-therapeutics-bispecific-pipeline-progress-and-strengthened-financial-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-lifts-price-target-and-reiterates-buy-on-context-therapeutics-bispecific-pipeline-progress-and-strengthened-financial-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.1056},{"period":"1month","weight":-0.2892},{"period":"3month","weight":-0.4025},{"period":"6month","weight":-0.7564},{"period":"1year","weight":-0.7494},{"period":"ytd","weight":-0.55}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.147177},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}